ArticleFrontiers in endocrinology2023
Value of machine learning-based transrectal multimodal ultrasound combined with PSA-related indicators in the diagnosis of clinically significant prostate cancer.
Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Identification of Factors Affecting Prostate Cancer Using Machine Learning Methods: A Systematic Review.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- Artificial intelligence for prostate cancer detection and risk stratification using transrectal ultrasound: a narrative review.Gland surgery · 2026Review
- Application and prospect of artificial intelligence in diagnostic imaging of prostate cancer.NPJ digital medicine · 2026Review
- Multiparametric MRI-based radiomics model integrating tumor lesion and periprostatic adipose tissue for predicting bone metastasis in prostate cancer.Frontiers in oncology · 2026Article
- Unveiling the role of harmonization on clinically significant prostate cancer detection using MRI.Scientific reports · 2025Article
- The diagnostic value of urinary exosomes in prostate cancer: a prospective multicenter study.BMC urology · 2025Article
- An overview of utilizing artificial intelligence in localized prostate cancer imaging.Expert review of medical devices · 2025Review
- Multi-branch CNNFormer: a novel framework for predicting prostate cancer response to hormonal therapy.Biomedical engineering online · 2024Article
- Radiogenomic analysis of ultrasound phenotypic features coupled to proteomes predicts metastatic risk in primary prostate cancer.BMC cancer · 2024Article
- Online COVID-19 diagnosis prediction using complete blood count: an innovative tool for public health.BMC public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the effect of transrectal multimodal ultrasound combined with serum prostate-specific antigen (PSA)-related indicators and machine learning for the diagnosis of clinically significant prostate cancer. Methods: Based on Gleason score of postoperative pathological results, the subjects were divided into clinically significant prostate cancer groups(GS>6)and non-clinically significant prostate cancer groups(GS ≤ 6). The independent risk factors were obtained by univariate logistic analysis. Artificial neural network (ANN), logistic regression (LR), support vector machine (SVM), decision tree (DT), random forest (RF), and K-nearest neighbor (KNN) machine learning models were combined with clinically significant prostate cancer risk factors to establish the machine learning model, calculate the model evaluation indicators, construct the receiver operating characteristic curve (ROC), and calculate the area under the curve (AUC). Results: Independent risk factor items (P< 0.05) were entered into the machine learning model. A comparison of the evaluation indicators of the model and the area under the ROC curve showed the ANN model to be best at predicting clinically significant prostate cancer, with a sensitivity of 80%, specificity of 88.6%, F1 score of 0.897, and the AUC was 0.855. Conclusion: Establishing a machine learning model by rectal multimodal ultrasound and combining it with PSA-related indicators has definite application value in predicting clinically significant prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.